Compare MPAA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPAA | EOLS |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.0M | 304.0M |
| IPO Year | 1994 | 2018 |
| Metric | MPAA | EOLS |
|---|---|---|
| Price | $10.08 | $4.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $17.40 |
| AVG Volume (30 Days) | 156.0K | ★ 1.1M |
| Earning Date | 02-09-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $770,636,000.00 | $285,823,000.00 |
| Revenue This Year | $9.76 | $13.70 |
| Revenue Next Year | $5.81 | $13.40 |
| P/E Ratio | $106.59 | ★ N/A |
| Revenue Growth | 2.24 | ★ 15.10 |
| 52 Week Low | $7.54 | $4.09 |
| 52 Week High | $18.12 | $17.12 |
| Indicator | MPAA | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 32.43 |
| Support Level | $9.29 | $4.09 |
| Resistance Level | $13.18 | $4.61 |
| Average True Range (ATR) | 0.69 | 0.27 |
| MACD | -0.36 | 0.02 |
| Stochastic Oscillator | 17.81 | 23.22 |
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard part in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.